GE's Pharma Ambitions Lead to a Lilly Deal
Executive Summary
GE Healthcare's joint research collaboration with Eli Lilly is small and easy to miss. It's very early stage and doesn't involve money exchanging hands. But it's the first manifestation of GE's efforts to expand its relationships with pharma companies following its acquisition of Amersham PLC. GE will comb Lilly's extensive molecular libraries for targets that could help diagnose Alzheimer's disease earlier. GE could turn these targets into imaging agents. Lilly is eager for tools to help diagnose and manage Alzheimer's disease because it has several Alzheimer's drugs in development.